A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

• Status: Terminated
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if CVX-241 (PF-05057459) is safe and tolerable when given as weekly infusions to adult patients with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Endothelial Growth Factors

Criteria

Inclusion Criteria:

• Confirmed solid tumors unresponsive to current therapy or for which there is no standard therapy.

• Stage 2 only: Histologically or cytologically documented EOC or PPC with < or equal to 3 previous anti-cancer therapies, but at least 1 prior platinum containing regimen.

• Adequate coagulation, liver, and renal function.

• Candidate for Dynamic Contrast-Enhanced Magnetic Resonance Imaging [DCE-MRI] evaluation

• Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1

Exclusion Criteria:

• History of clinically significant toxicity to Vascular Endothelial Growth Factor [VEGF] inhibition.

• Evidence of bleeding problems.

• Uncontrolled hypertension.

• Patients with primary brain cancer and/or non-small cell lung cancer of squamous cell histology